In the latest developments in the pharmaceutical sector, Moderna Inc’s lawsuit alleging COVID-19 vaccine patent infringement by Pfizer Inc. and BioNTech has been momentarily slowed down. Following a decision from a Massachusetts federal judge on Friday, proceedings have been set aside until the Patent Trial and Appeal Board handles a review on two crucial patents involved in the matter.
This interruption has been permitted despite opposition from Moderna. Notably, both Pfizer and BioNTech are the defendants in this increasingly closely-watched case. The temporary pause symbolizes the importance the court places on the Patent Trial and Appeal Board’s review, likely to set precedent for further legal action in the sector.
Details of the case and further stark updates continue to be closely monitored by legal and corporate professionals alike, and can be examined in detail in the case’s original documentation available through the Law360 report.